# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Stifel analyst Rick Wise maintains Artivion (NYSE:AORT) with a Buy and raises the price target from $22 to $25.
Needham analyst Mike Matson maintains Artivion (NYSE:AORT) with a Buy and raises the price target from $25 to $30.
The Company expects revenues to be in the range of $386 to $396 million compared to the previously articulated range of $382 to...
Artivion (NYSE:AORT) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.11) by 154...
5-Year Real-World Safety and Efficacy Data from On-X Aortic Heart Valve Low INR Post-Market Study Demonstrate Even Better Patie...